Mineralys Surges 41% on Lorundrostat Kidney Disease Data at ASN 2026
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
mineralyslorundrostat
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Investing.com reported on May 30, 2026, that Mineralys Therapeutics published new clinical data for its lead drug candidate lorundrostat. The findings, from a cohort of patients with resistant hypertension and chronic kidney disease, were presented at the American Society of Nephrology Kidney Week 2026 conference. The data announcement propelled Mineralys shares to a 41% intraday gain, a move that significantly outperformed the broader biotech sector represented by the SPDR S&P Biotech ETF, which was up 1.2% on the same day.
The announcement arrives amid a renewed investor focus on cardiorenal therapies following a decade of limited innovation. The last major paradigm shift occurred with the 2015 EMPA-REG OUTCOME trial for SGLT2 inhibitors, which demonstrated cardiovascular and renal benefits and reshaped standard of care. Today's macro backdrop features persistently elevated rates of hypertension and chronic kidney disease, conditions that drive immense healthcare costs and for which new, targeted treatments are in high demand. The catalyst for Mineralys's surge is the specific demonstration of lorundrostat's effect in a high-risk CKD population, a key data gap that needed filling to expand the drug's potential label beyond resistant hypertension alone.
Chronic kidney disease affects over 850 million people globally, with hypertension a leading cause. The market for advanced CKD therapies is projected to reach $48 billion by 2030. Mineralys's data directly addresses a critical unmet need within this massive market, providing a concrete growth vector beyond its initial target indication. The timing is also crucial as the company prepares for the Phase 3 ADVANTAGE-T trial readout, making this interim data a key de-risking event for investors.
The presented data came from a predefined analysis of 49 patients with stage 2-4 CKD enrolled in the Phase 2 Target-HTN trial. After 8 weeks of treatment, lorundrostat achieved a mean reduction in systolic blood pressure of 12.4 mmHg from baseline in these patients. This result is consistent with the previously reported 12.9 mmHg reduction in the overall trial population, indicating efficacy is maintained in a renally impaired cohort.
A key safety metric, the estimated glomerular filtration rate, remained stable throughout the treatment period. This stability is a critical differentiator for nephrologists when evaluating new antihypertensives. The stock closed the session at $18.74, up from a previous close of $13.29, adding approximately $280 million to the company's market capitalization. Peer company Merck, a leader in the cardiorenal space with its drug finerenone, saw its stock trade flat on the day, highlighting the event-specific nature of Mineralys's move.
The immediate second-order effect is a repricing of competitive risk for other developers in the resistant hypertension and CKD space. Companies like CinCor Pharma, now part of AstraZeneca, and Idorsia with their aprocitentan may face increased investor scrutiny regarding their drugs' renal profiles. Conversely, the positive data could buoy sentiment for other biotechs targeting aldosterone synthase, such as Spruce Biosciences, though their programs are in earlier stages. A direct beneficiary of the renewed focus is likely IQVIA, as clinical trial activity in nephrology may see an uptick.
A significant limitation of the data is the small patient cohort size of 49, which limits statistical power for assessing rare adverse events. Long-term renal outcomes beyond 8 weeks also remain unknown. Positioning data shows a clear flow into Mineralys from generalist healthcare funds that had been awaiting this specific renal data point. Short interest, which was elevated at 12% of float prior to the announcement, likely contributed to the sharpness of the squeeze as positions were covered.
The primary near-term catalyst is the initiation and eventual readout of the pivotal Phase 3 ADVANTAGE-T trial in treatment-resistant hypertension, expected to begin enrollment in Q3 2026. Investors should monitor the company's cash runway, currently projected into early 2028, against the burn rate of this large trial. A secondary catalyst is potential partnership discussions, which may accelerate following this de-risking event, with large pharma companies like Novartis or Bayer as logical candidates given their cardiovascular portfolios.
Key levels to watch for the stock include the $20 psychological resistance and the 200-day moving average, currently around $14.50, which may now act as support. For the broader sector, the SPDR S&P Biotech ETF holding above its 50-day moving average will indicate whether the positive sentiment is contagious or isolated to Mineralys. The next major nephrology conference, the World Congress of Nephrology in April 2027, will be a venue for updated, longer-term data.
Lorundrostat is an oral, once-daily inhibitor of aldosterone synthase, an enzyme key to producing the hormone aldosterone. Excessive aldosterone drives high blood pressure and contributes to kidney and heart damage. By selectively inhibiting its production at the source, lorundrostat aims to lower blood pressure and provide organ protection without the side effects of traditional aldosterone receptor blockers, such as high potassium levels. Its mechanism is distinct from recently approved cardiorenal drugs like SGLT2 inhibitors and non-steroidal MRAs.
The data strengthens Mineralys's position in the chronic kidney disease segment but does not directly challenge Merck's established drug, finerenone. Finerenone is a non-steroidal mineralocorticoid receptor antagonist approved for reducing CKD progression and cardiovascular risk in type 2 diabetes patients. Lorundrostat, by contrast, targets aldosterone production upstream. The two drugs could theoretically be used in combination, addressing different parts of the same pathological pathway. The market is large enough for multiple mechanisms, but Mineralys now has concrete data to support its entry into the CKD conversation.
The principal risks are the outcomes of the large, expensive Phase 3 trials required for regulatory approval. While Phase 2 data is promising, it must be replicated in a much larger and more diverse population. Long-term safety, particularly regarding hormone levels beyond aldosterone, requires thorough monitoring. the commercial landscape is competitive, with several new drug classes vying for market share. Success will depend not only on efficacy but also on demonstrating a superior safety and tolerability profile that justifies its use in a crowded treatment algorithm.
The positive renal data de-risks lorundrostat's development path and validates its potential in the massive chronic kidney disease market.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.